Reaction
Abdominal Cavity Drainage reporting signals
As of the last recalculation, Abdominal Cavity Drainage appears in 418 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is EPOPROSTENOL (PRR 145.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Epoprostenol | 35 | 145.2 | 145.6 |
| Selexipag | 24 | 49.0 | 49.1 |
| Macitentan | 55 | 45.4 | 45.4 |
| Rifaximin | 18 | 44.7 | 44.7 |
| Sorafenib | 16 | 39.8 | 39.9 |
| Niraparib | 16 | 37.3 | 37.3 |
| Sofosbuvir | 14 | 36.5 | 36.5 |
| Lanreotide Acetate | 4 | 25.6 | 25.7 |
| Riociguat | 16 | 25.4 | 25.4 |
| Bosentan | 18 | 18.5 | 18.5 |
| Fam-Trastuzumab Deruxtecan-Nxki | 3 | 14.9 | 14.9 |
| Sevelamer Carbonate | 3 | 13.1 | 13.1 |